Seer, Inc. (NASDAQ:SEER - Get Free Report) CEO Omid Farokhzad sold 8,068 shares of Seer stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $2.24, for a total value of $18,072.32. Following the sale, the chief executive officer now directly owns 1,428,217 shares in the company, valued at approximately $3,199,206.08. The trade was a 0.56 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Seer Trading Down 3.0 %
Shares of SEER traded down $0.07 on Friday, reaching $2.26. The stock had a trading volume of 175,122 shares, compared to its average volume of 133,097. Seer, Inc. has a 12-month low of $1.51 and a 12-month high of $2.63. The company has a 50-day simple moving average of $2.36 and a 200-day simple moving average of $2.07.
Hedge Funds Weigh In On Seer
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC purchased a new stake in shares of Seer in the 2nd quarter worth about $30,000. Y Intercept Hong Kong Ltd purchased a new stake in Seer in the fourth quarter worth about $36,000. Quadrature Capital Ltd increased its stake in shares of Seer by 301.7% during the third quarter. Quadrature Capital Ltd now owns 57,088 shares of the company's stock valued at $112,000 after purchasing an additional 42,875 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Seer during the third quarter valued at approximately $123,000. Finally, Barclays PLC lifted its holdings in shares of Seer by 34.1% during the third quarter. Barclays PLC now owns 64,426 shares of the company's stock valued at $127,000 after purchasing an additional 16,382 shares during the last quarter. Hedge funds and other institutional investors own 75.20% of the company's stock.
About Seer
(
Get Free Report)
Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
Featured Articles
Before you consider Seer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seer wasn't on the list.
While Seer currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
